Nuclear Medicine and Biology
Volume 35, Issue 1 , Pages 83-90 , January 2008

A novel gallium bisaminothiolate complex as a myocardial perfusion imaging agent

  • Karl Plössl

      Affiliations

    • Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    • ,
  • Rajesh Chandra

      Affiliations

    • Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    • ,
  • Wenchao Qu

      Affiliations

    • Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    • ,
  • Brian P. Lieberman

      Affiliations

    • Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    • ,
  • Mei-Ping Kung

      Affiliations

    • Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    • ,
  • Rong Zhou

      Affiliations

    • Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    • ,
  • Bin Huang

      Affiliations

    • Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    • ,
  • Hank F. Kung

      Affiliations

    • Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    • Department of Pharmacology, University of Pennsylvania, Philadelphia, PA 19104, USA
    • Corresponding Author InformationCorresponding author. Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA. Tel.: +1 215 662 3096; fax: +1 215 349 5035.

Received 16 June 2007 ,Revised 9 August 2007 ,Accepted 11 August 2007.

References 

  1. Slart RH, Bax JJ, van Veldhuisen DJ, van der Wall EE, Dierckx RA, Jager PL. Imaging techniques in nuclear cardiology for the assessment of myocardial viability. Int J Cardiovasc Imaging. 2006;22:63–80
  2. Naruse H, Daher E, Sinusas A, Jain D, Natale D, Mattera J, et al. Quantitative comparison of planar and SPECT normal data files of thallium-201, technetium-99m-sestamibi, technetium-99m-tetrofosmin and technetium-99m-furifosmin. J Nucl Med. 1996;37:1783–1788
  3. Di Carli MF, Dorbala S. Cardiac PET-CT. J Thorac Imaging. 2007;22:101–106
  4. Ehrhardt GJ, Welch MJ. A new germanium-68/gallium-68 generator. J Nucl Med. 1978;19:925–929
  5. Neirinckx RD, Davis MA. Potential column chromatography generators for ionic Ga-68: I. Inorganic substrates. J Nucl Med. 1979;20:1075–1079
  6. Loc'h C, Maziere B, Comar D. A new generator for ionic gallium-68. J Nucl Med. 1980;21:171–173
  7. Neirinckx RD, Davis MA. Potential column chromatography for ionic Ga-68: II. Organic ion exchangers as chromatographic supports. J Nucl Med. 1980;21:81–83
  8. Schuhmacher J, Maier-Borst W. A new 68Ge/68Ga radioisotope generator system for production of 68Ga in dilute HCl. Int J Appl Radiat Isot. 1981;32:31–36
  9. Nakayama M, Haratake M, Ono M, Koiso T, Harada K, Nakayama H, et al. A new 68Ge/68Ga generator system using an organic polymer containing N-methylglucamine groups as adsorbent for 68Ge. Int J Appl Radiat Isot. 2003;58:9–14
  10. Breeman WA, Verbruggen AM. The (68)Ge/(68)Ga generator has high potential, but when can we use (68)Ga-labelled tracers in clinical routine?. Eur J Nucl Med Mol Imaging. 2007;34:978–981
  11. Maecke HR, Hofmann M, Haberkorn U. (68)Ga-labeled peptides in tumor imaging. J Nucl Med. 2005;46(Suppl 1):172S–178S
  12. Meyer GJ, Macke H, Schuhmacher J, Knapp WH, Hofmann M. 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging. 2004;31:1097–1104
  13. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006;36:228–247
  14. von Falck C, Boerner AR, Galanski M, Knapp WH. Neuroendocrine tumour of the mediastinum: fusion of (18)F-FDG and (68)Ga-DOTATOC PET/CT datasets demonstrates different degrees of differentiation. Eur J Nucl Med Mol Imaging. 2007;34:812
  15. Velikyan I, Sundberg AL, Lindhe O, Hoglund AU, Eriksson O, Werner E, et al. Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med. 2005;46:1881–1888
  16. Zhang H, Schuhmacher J, Waser B, Wild D, Eisenhut M, Reubi JC, et al. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging. 2007;34:1198–1208
  17. Dimitrakopoulou-Strauss A, Georgoulias V, Eisenhut M, Herth F, Koukouraki S, Macke HR, et al. Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using(68)Ga-DOTATOC PET and comparison with (18)F-FDG PET. Eur J Nucl Med Mol Imaging. 2006;33:823–830
  18. Koukouraki S, Strauss LG, Georgoulias V, Eisenhut M, Haberkorn U, Dimitrakopoulou-Strauss A. Comparison of the pharmacokinetics of (68)Ga-DOTATOC and [(18)F]FDG in patients with metastatic neuroendocrine tumours scheduled for (90)Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging. 2006;33:1115–1122
  19. Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?. Eur J Nucl Med Mol Imaging. 2007;34:982–993
  20. Antunes P, Ginj M, Walter MA, Chen J, Reubi JC, Maecke HR. Influence of different spacers on the biological profile of a DOTA–somatostatin analogue. Bioconjug Chem. 2007;18:84–92
  21. van Hagen PM, Breeman WA, Reubi JC, Postema PT, van den Anker-Lugtenburg PJ, Kwekkeboom DJ, et al. Visualization of the thymus by substance P receptor scintigraphy in man. Eur J Nucl Med. 1996;23:1508–1513
  22. Behr TM, Behe MP. Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med. 2002;32:97–109
  23. Ginj M, Chen J, Walter MA, Eltschinger V, Reubi JC, Maecke HR. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res. 2005;11:1136–1145
  24. van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW, et al. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med. 2006;47:1599–1606
  25. Frilling A, Weber F, Saner F, Bockisch A, Hofmann M, Mueller-Brand J, et al. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery. 2006;140:968–976[discussion, 76–7]
  26. Kung HF, Liu B-L, Mankoff D, Kung M-P, Billings JJ, Francesconi LC, et al. A new myocardial imaging agent: synthesis, characterization, and biodistribution of gallium-68-BAT-TECH. J Nucl Med. 1990;31:1635–1640
  27. Francesconi LC, Liu B-L, Billings JJ, Carroll PJ, Graczyk G, Kung HF. Synthesis, characterization and solid state structure of a neutral gallium(III) amino thiolate complex: a potential radiopharmaceutical for PET imaging. J Chem Soc Chem Comm. 1991;2:94–95
  28. Zheng YY, Saluja S, Yap GP, Blumenstein M, Rheingold AL, Francesconi LC. Gallium and indium complexes of bis(amino thiol) (N(2)S(2)) ligands. Inorg Chem. 1996;35:6656–6666
  29. Cutler CS, Giron MC, Reichert DE, Snyder AZ, Herrero P, Anderson CJ, et al. Evaluation of gallium-68 tris(2-mercaptobenzyl)amine: a complex with brain and myocardial uptake. Nucl Med Biol. 1999;26:305–316
  30. Bandarage UK, Chen L, Fang X, Garvey DS, Glavin A, Janero DR, et al. Nitrosothiol esters of diclofenac: synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs. J Med Chem. 2000;43:4005–4016
  31. Green MA, Welch MJ, Huffman JC. Synthesis and crystallographic characterization of a gallium salicylaldimine complex of radiopharmaceutical interest. J Am Chem Soc. 1984;106:3689–3691
  32. Craig AS, Parker D, Adams H, Bailey NA. Stability, Ga-71 NMR, and crystal-structure of a neutral gallium (iii) complex of 1,4,7-triazacyclononanetriacetate — a potential radiopharmaceutical. J Chem Soc — Chem Commun. 1989;1793
  33. Moore DA, Fanwick PE, Welch MJ. A novel hexachelating amino–thiol ligand and its complex with gallium (III). Inorg Chem. 1990;29:672–676
  34. Carty AJ, Dymock KR, Boorman PM. Coordination complexes of gallium (III) and indium (III) halides: VI. The structures of gallium (III) halide complexes with 1,10-phenanthroline. Can J Chem. 1970;48:3524–3529
  35. Cooper DA, Rettig SJ, Storr A, Trotter J. The 2-mercapto-1-methylimidazolyl moiety as a bridging ligand in complexes of gallium, rhenium, and molybdenum. Can J Chem. 1986;64:1643–1651
  36. Tsang BW, Mathias CJ, Fanwick PE, Green MA. Structure–distribution relationships for metal-labeled myocardial imaging agents: comparison of a series of cationic gallium (III) complexes with hexadentate bis(salicylaldimine) ligands. J Med Chem. 1994;37:4400–4406
  37. Dymock K, Palenik GJ, Carty AJ. Preparation and crystal structure of a novel hydroxo-bridged gallium complex, di-m-hydroxybis[chloro[methyl[(6-methyl-2-pyridyl)methyl](2-pyridylmethyl)amine]gallium(III)] dichloride hydrate. J Chem Soc Chem Commun. 1972;1218–1219
  38. Dymock K, Palenik GJ. Tris(acetylacetonato)gallium(III). Acta Crystallogr B. 1974;30:1364–1366
  39. Johnson LL. Myocardial perfusion imaging with technetium-99m-teboroxime. J Nucl Med. 1994;35:689–692
  40. Berman DS, Kiat H, Maddahi J. The new 99mTc myocardial perfusion imaging agents: 99mTc-sestamibi and 99mTc-teboroxime. Circulation. 1991;84:I7–I21
  41. Senda M, Nishizawa S, Yonekura Y, Tamaki N, Saji H, Mukai T, et al. A new subtraction method for obtaining myocardial perfusion images with oxygen-15 water and positron emission tomography. Ann Nucl Med. 1988;2:101–106
  42. Stankewicz MA, Mansour CS, Eisner RL, Churchwell KB, Williams BR, Sigman SR, et al. Myocardial viability assessment by PET: (82)Rb defect washout does not predict the results of metabolic-perfusion mismatch. J Nucl Med. 2005;46:1602–1609
  43. Johnson NP, Gould KL. Clinical evaluation of a new concept: resting myocardial perfusion heterogeneity quantified by Markovian analysis of PET identifies coronary microvascular dysfunction and early atherosclerosis in 1,034 subjects. J Nucl Med. 2005;46:1427–1437
  44. Lodge MA, Braess H, Mahmoud F, Suh J, Englar N, Geyser-Stoops S, et al. Developments in nuclear cardiology: transition from single photon emission computed tomography to positron emission tomography–computed tomography. J Invasive Cardiol. 2005;17:491–496
  45. Di Carli MF, Dorbala S. Integrated PET/CT for cardiac imaging. Q J Nucl Med Mol Imaging. 2006;50:44–52
  46. Machac J. Cardiac positron emission tomography imaging. Semin Nucl Med. 2005;35:17–36

PII: S0969-8051(07)00219-3

doi: 10.1016/j.nucmedbio.2007.08.002

Nuclear Medicine and Biology
Volume 35, Issue 1 , Pages 83-90 , January 2008

Article Tools

* Image Usage & Resolution